Studies have shown that IL-6, a cytokine induced by NF-κB, promotes DLBCL migration by activating the migration mechanism driven by JAK-STAT, promotes the progression and drug resistance of DLBCL and is related to the poor prognosis of DLBCL patients [30–32]. Here, NFKB1 is linked to diffuse large B-cell lymphoma.